Arrowhead Research | ARWR - Ebitda



金融业
股票价格
USD
资产
USD 2.11B
现金及等价物
USD 19.69M
流动资产
USD 1.67B
流动负债
USD 283.35M
债务
USD 983.69M
EBIT
USD -154.34M
EBITDA
USD -147.68M
员工
711
EPS每股收益
USD -1.36
股本和储备
USD 465.53M
销售毛利
USD 75.25M
债务利息支出
USD 24.56M
利息收入
USD 16.94M
贷款资金
USD 824.07M
市值
USD 10.5B
净收入
USD -194.28M
营业费用
USD 245.35M
营业利润
USD -170.09M
普通股股本
USD 141.14M
PE价格收益
39.19
税前利润
USD -178.91M
销售收入
USD 75.23M
销售和管理费用
USD 46.63M
股票
USD -173.09M
贸易债权人
USD 27.78M
应收帐款人
USD 8.56M


Ebitda 更改 日
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD -147.68M 40.33M 2026-06
Heron Therapeutics USD -3.88M 5.63M 2024-09
Incyte USD 778.57M 410.6M 2026-06
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Ligand Pharmaceuticals USD -14.3M 81.08M 2026-03
Merck USD -1.54B 7.84B 2026-03
Moderna USD -1.26B 468M 2026-03
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Novartis USD 6.48B 1.19B 2026-06
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
TG Therapeutics USD 26.9M 1.21M 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06
Xencor USD -34.63M 86.74M 2026-06